Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)	Up to 3.5 years
Primary	Parts 1 and 3: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)	Up to Day 21
Secondary	Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	Up to 3.5 years
Secondary	Duration of Response (DOR) per RECIST v1.1	Up to 3.5 years
Secondary	Time to Response (TTR) per RECIST v1.1	Up to 3.5 years
Secondary	Disease Control Rate (DCR) per RECIST v1.1	Up to 3.5 years
Secondary	Progression-free Survival (PFS) per RECIST v1.1	Up to 3.5 years
Secondary	Time to Progression (TTP) per RECIST v1.1	Up to 3.5 years
Secondary	Time to Subsequent Therapy	Up to 3.5 years
Secondary	Overall survival (OS)	Up to 3.5 years
Secondary	Serum Tarlatamab Concentrations	Up to Week 36

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07531095/registered